Nov 6, 2006 by Brian LawlerNeurocrine's Big HeadacheAnother clinical trial means a steep drop in share price, but the company's not dead yet.
Nov 6, 2006 by Brian LawlerNo Worries About CephalonThis solid biopharma ups its yearly guidance -- for the fourth time.
Nov 6, 2006 by Brian LawlerOne Step at a TimeZymoGenetics' management is still facing challenges, but so far it has proved itself worthy.
Nov 3, 2006 by Brian LawlerNothing's Wrong With ViroPharmaDespite potential generic competition on the horizon, the company is going strong.
Nov 3, 2006 by Brian LawlerEncysive's Tempting ProspectsThings are looking up for Encysive on the heels of a recent drug approval.
Nov 3, 2006 by Brian LawlerNektar Worth Waiting For?Investors might be getting impatient, but the new insulin the company makes is special.
Nov 3, 2006 by Brian LawlerAcorda's Wild RidePositive trials help propel the stock to seven times its yearly low.
Nov 2, 2006 by Brian LawlerAngiotech's Study TroublesThe results of recent studies in medical journals have brought the company's forecasts down.
Nov 2, 2006 by Brian LawlerBioMarin's in Good HealthThis biopharma has a leg up on the competition by getting its finances in order.
Nov 2, 2006 by Brian LawlerAspreva's Growing Cash PileThe drug developer released its quarterly results yesterday, but investors already know what they'll look like.
Nov 1, 2006 by Brian LawlerBiogen Idec's Booming ResultsA surprise sales surge fuels impressive revenues.
Nov 1, 2006 by Brian LawlerWaiting for CVT's Trial ResultsThe biopharm reported third-quarter earnings that were mostly as expected yesterday.
Nov 1, 2006 by Brian LawlerLe Generic Excuse for SanofiGenerics dented sales of Plavix, leading to lower sales overall.
Nov 1, 2006 by Brian LawlerMylan: Anything but GenericRevenues and earnings soar in the generic drugmaker's second quarter.
Oct 31, 2006 by Brian LawlerA Foolish Trick: ElanDebt is coming due, and there's too much reliance on a single drug.
Oct 31, 2006 by Brian LawlerA Foolish Treat: Pain TherapeuticsDespite its name, this pharma could very well bring investors pleasure.
Oct 31, 2006 by Brian LawlerA Biotech FrankenstockOne Fool assembles the perfect biotechnology beast.
Oct 31, 2006 by Brian LawlerA Look Inside the Biotech Haunted HouseA peek inside a scary place full of the ghosts of failed biotechs past like Large Scale Biology and Targeted Genetics.
Oct 31, 2006 by Brian LawlerNovo Nordisk Still Knows SalesThere's more competition in diabetes care now, but the company is thriving.
Oct 30, 2006 by Brian LawlerVertex's Healthy Trial ResultsShares of the pharmaceutical company were up on the release of positive clinical trial data.
